Demangel Caroline, Garnier Thierry, Rosenkrands Ida, Cole Stewart T
Unité de Génétique Moléculaire Bactérienne, Institut Pasteur, 28 Rue du Dr Roux, 75724 Paris Cedex 15, France.
Infect Immun. 2005 Apr;73(4):2190-6. doi: 10.1128/IAI.73.4.2190-2196.2005.
In silico analysis reveals that most protective antigens expressed by the antituberculous vaccine Mycobacterium bovis BCG (BCG) are conserved in M. avium, supporting the hypothesis that exposure to environmental mycobacteria generates cross-reactive immune responses blocking BCG activity. We investigated the impact of sensitization with M. avium, M. scrofulaceum, or M. vaccae on the protective efficacy of a recombinant BCG strain expressing RD1 antigens (BCG::RD1), using a mouse model of experimental tuberculosis (TB). No evidence that the RD1-encoded antigens ESAT-6, CFP-10, and PPE68 were expressed by these environmental strains could be demonstrated by Western blot analysis. Mice sensitized with each of these strains did not prime cellular immune responses cross-reacting with the immunodominant ESAT-6. Importantly, clearance of BCG::RD1 from the lungs and spleens of mice exposed to each of the environmental strains before vaccination was minimal compared to that of BCG. In mice sensitized with M. avium, increased persistence of BCG::RD1 correlated with stronger antimycobacterial gamma interferon responses and enhanced protection against aerosol infection with M. tuberculosis, compared to BCG. In contrast, animals exposed to M. scrofulaceum or M. vaccae prior to vaccination with BCG or BCG::RD1 were better protected against TB than were the unsensitized controls. Our results suggest that the inhibitory effect of environmental mycobacteria on the protective efficacy of BCG depends critically on the extent of cross-recognition of antigens shared with the vaccine. In hosts sensitized with M. avium, potent immunogenicity of ESAT-6 and increased persistence of BCG::RD1 may allow this recombinant vaccine to overcome preexisting antimycobacterial responses.
计算机模拟分析表明,抗结核疫苗牛分枝杆菌卡介苗(BCG)表达的大多数保护性抗原在鸟分枝杆菌中是保守的,这支持了以下假设:暴露于环境分枝杆菌会产生交叉反应性免疫反应,从而阻断BCG的活性。我们使用实验性结核病(TB)小鼠模型,研究了用鸟分枝杆菌、瘰疬分枝杆菌或母牛分枝杆菌致敏对表达RD1抗原的重组BCG菌株(BCG::RD1)保护效力的影响。蛋白质印迹分析未发现这些环境菌株表达RD1编码的抗原ESAT-6、CFP-10和PPE68的证据。用这些菌株中的每一种致敏的小鼠均未引发与免疫显性ESAT-6发生交叉反应的细胞免疫反应。重要的是,与接种BCG的小鼠相比,在接种疫苗前暴露于每种环境菌株的小鼠的肺和脾中,BCG::RD1的清除率极低。在用鸟分枝杆菌致敏的小鼠中,与BCG相比,BCG::RD1持续存在时间的增加与更强的抗分枝杆菌γ干扰素反应以及对结核分枝杆菌气溶胶感染的增强保护相关。相反,在接种BCG或BCG::RD1之前暴露于瘰疬分枝杆菌或母牛分枝杆菌的动物比未致敏的对照对TB的保护更好。我们的结果表明,环境分枝杆菌对BCG保护效力的抑制作用关键取决于与疫苗共享的抗原的交叉识别程度。在用鸟分枝杆菌致敏的宿主中,ESAT-6的强免疫原性和BCG::RD1持续存在时间的增加可能使这种重组疫苗克服先前存在的抗分枝杆菌反应。